Identification of Novel RD1 Antigens and Their Combinations for Diagnosis of Sputum Smear−/Culture+ TB Patients

Liu, Zhiqiang; Qie, Shuang; Li, Lili; Xiu, Bingshui; Yang, Xinglun; Dai, Zhenhua; Zhang, Xuhui; Duan, Cuimi; Que, Haiping; Zhao, Ping; Johnson, Heather; Zhang, Heqiu; Xia, Feng

doi:10.1155/2016/7486425

Cited by 4 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 , 41 Proteins, such as Rv1985c, Rv3871, Rv3876 and Rv3879, that originated from RD 2 and 1 were demonstrated to be promising antigens in TB diagnostics, while Rv2659c was more suitable for diagnosis in latent TB patients. 23 , 27 , 30 In our study, the results of anti-Rv0310c-E, based on RD 8, and anti-Rv1255c-E, based on RD 10, IgG titers were significantly higher in TB patients than controls. Using ROC analysis, we found that anti-Rv0310c-E and anti-Rv1255c-E IgG antibodies exhibited similar AUC values.…”

Section: Discussionsupporting

confidence: 44%

“…The optimal operating point for each antigen at the maximum value of YI was calculated from the ROC analysis, and the corresponding sensitivity and specificity were determined. 30 The overall diagnostic performances of individual antigens for active TB are shown in Table 3 . The best performing antigen in the SPPT group was Rv0310c-E (YI: 0.5602), while it was Rv1255c-E (YI: 0.5674) in the SNPT group.…”

Section: Resultsmentioning

confidence: 99%

“…29 The optimal operating point was determined via Youden’s index (YI) according to a method previously reported. 30 The sensitivity and specificity of each operating point in the ROC curve and combined antigens were conditionally calculated using Excel, followed by calculation of YI at each point (YI=sensitivity+specificity−1). When evaluating the diagnostic performance of combined antigens in sera, any single positive was defined to be positive in combination, and the corresponding sensitivity and specificity were recorded.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis ofMycobacterium tuberculosisinfection

Luo

Zhu

Yue

et al. 2017

Emerging Microbes & Infections

View full text Add to dashboard Cite

This study aimed to identify novel immunogenic epitopes from Mycobacterium tuberculosis (MTB) that could be used in tuberculosis (TB) diagnostics. To determine the diagnostic potential of mycobacterial antigens in serodiagnosis of TB, 256 patients were enrolled in a study and divided into two groups: 126 smear-positive pulmonary TB patients (SPPT) and 130 smear-negative pulmonary TB patients (SNPT); 152 bacillus Calmette-Guerin (BCG)-vaccinated healthy people were used as a control. Murine results showed that antigens Rv0310c-E from RD 8 and Rv1255c-E from RD 10 were strongly immunogenic to Th1 cells and induced a great humoral response. Receiver operating characteristic analysis indicated that Rv0310c-E (area under the curve (AUC): 0.800) and Rv1255c-E (AUC: 0.808) performed better than ESAT-6 (AUC: 0.665) and CFP-10 (AUC: 0.623) proteins but were comparable with Rv3425 (AUC: 0.788) protein in a human serum IgG analysis. Rv0310c-E demonstrated the highest diagnostic ability for the SPPT group (Youden index: 0.5602, sensitivity: 69.84%, specificity: 86.18%), while Rv1255c-E demonstrated the highest diagnostic ability for the SNPT group (Youden index: 0.5674, sensitivity: 73.84%, specificity: 82.89%). In addition, combination analysis found that antigen Rv0310c-E, coupled with the Rv3425 protein (Youden index: 0.6098, sensitivity: 87.30%, specificity: 73.68%) had the strongest performance for TB diagnostics of the SPPT group, and the single antigen Rv1255c-E was strongest for the SNPT group. These results suggest that antigens Rv0310c-E and Rv1255c-E are potential antigens for TB serodiagnostic tests, which may facilitate detection of MTB in smear-negative and smear-positive patients.

show abstract

Section: Discussionsupporting

confidence: 44%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis ofMycobacterium tuberculosisinfection

Luo

Zhu

Yue

et al. 2017

Emerging Microbes & Infections

View full text Add to dashboard Cite

show abstract

“…Thus, Liu et al . combined Rv3871, Rv3876, and Rv3879 proteins and improved the diagnostic ability in PTB‐SN(Liu et al ., ). In our study, parallel tests by combining two and three antigens among Rv0222, Rv3403c and ESAT6/CFP10 were similarly investigated to improve the sensitivity of TB diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…The coincidence rates of Rv0222, Rv3403c and ESAT6/CFP10 proteins in the diagnosis of PTB-SP, PTB-SN, and EPTB groups were not high, indicating that immune recognition of antigens varies in different patients, and that no definite antigen was identified in all or a majority of samples (Lyashchenko et al, 1998). Thus, Liu et al combined Rv3871,Rv3876, and Rv3879 proteins and improved the diagnostic ability in PTB-SN (Liu et al, 2016). In our study, parallel tests by combining two and three antigens among Rv0222, Rv3403c and ESAT6/ CFP10 were similarly investigated to improve the sensitivity of TB diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Identification of new diagnostic biomarkers for Mycobacterium tuberculosis and the potential application in the serodiagnosis of human tuberculosis

Ren

JinLi

Chen

et al. 2018

Microbial Biotechnology

View full text Add to dashboard Cite

Summary Mycobacterium tuberculosis (M. tuberculosis) regions of difference (RD) encode proteins which are potentially useful as diagnostic reagents for tuberculosis (TB). In this study, 75 genes from M. tuberculosis RD1‐RD16 were successfully cloned from which 68 proteins were expressed and purified. Three serum pools from patients with pulmonary TB (PTB), extra‐pulmonary tuberculosis (EPTB) and healthy controls (HC) were used to preliminarily screen individual RD proteins. The OD 630 ratio of the PTB or EPTB to the HC group ≥ 2‐fold was positive. As a result, 29 proteins were obtained. The serological response to the identified antigens was further verified using 58 PTB samples with 38 sera from smear‐positive PTB (PTB‐SP) patients and 20 sera from smear‐negative PTB (PTB‐SN) patients, 16 EPTB samples, 42 latent M. tuberculosis infection samples and 40 HCs by indirect ELISA. With respect to the PTB diagnosis, receiver operating characteristic analysis showed that Rv0222 [area under the curve (AUC), 0.8129; 95% confidence interval (CI), 0.7280–0.8979] and Rv3403c (AUC, 0.8537; 95% CI, 0.7779–0.9294) performed better than ESAT6/CFP10 (AUC, 0.7435; 95% CI, 0.6465–0.8406). Rv0222 and Rv3403c demonstrated the highest diagnostic ability in the PTB‐SP group (sensitivity, 86.8%; specificity, 80%), while Rv3403c demonstrated the highest diagnostic ability in the PTB‐SN group (sensitivity, 70%; specificity, 80%). With respect to the EPTB diagnosis, Rv0222 exhibited the highest diagnostic value (AUC, 0.7523; sensitivity, 68.8%; specificity, 87.5%). In addition, the combination of Rv0222 and Rv3403c improved the test for PTB‐SN. These results indicate that Rv0222 and Rv3403c would be potential diagnostic biomarkers for active TB serodiagnosis. Mouse experiments demonstrated that Rv0222 and Rv3403c elicited specific cellular and humoral responses which were characterized by production of IFN‐γ, IgG1, and IgG2a, but a higher level of IgG1 than IgG2a.

show abstract

A novel multi-component protein vaccine ECP001 containing a protein polypeptide antigen nPstS1 riching in T-cell epitopes showed good immunogenicity and protection in mice

Fan

Luan

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB) is an infectious disease that seriously affects human health. Until now, the only anti-TB vaccine approved for use is the live attenuated Mycobacterium bovis (M. bovis) vaccine — BCG vaccine, but its protective efficacy is relatively low and does not provide satisfactory protection against TB in adults. Therefore, there is an urgent need for more effective vaccines to reduce the global TB epidemic. In this study, ESAT-6, CFP-10, two antigens full-length and the T-cell epitope polypeptide antigen of PstS1, named nPstS1, were selected to form one multi-component protein antigens, named ECP001, which include two types, one is a mixed protein antigen named ECP001m, the other is a fusion expression protein antigen named ECP001f, as candidates for protein subunit vaccines. were prepared by constructing one novel subunit vaccine by mixing or fusing the three proteins and combining them with aluminum hydroxide adjuvant, and the immunogenicity and protective properties of the vaccine was evaluated in mice. The results showed that ECP001 stimulated mice to produce high titre levels of IgG, IgG1 and IgG2a antibodies; meanwhile, high levels of IFN-γ and a broad range of specific cytokines were secreted by mouse splenocytes; in addition, ECP001 inhibited the proliferation of Mycobacterium tuberculosis in vitro with a capacity comparable to that of BCG. It can be concluded that ECP001 is a novel effective multicomponent subunit vaccine candidate with potential as BCG Initial Immunisation-ECP001 Booster Immunisation or therapeutic vaccine for M. tuberculosis infection.

show abstract

Identification of Novel RD1 Antigens and Their Combinations for Diagnosis of Sputum Smear−/Culture+ TB Patients

Cited by 4 publications

References 34 publications

Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis ofMycobacterium tuberculosisinfection

Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis ofMycobacterium tuberculosisinfection

Identification of new diagnostic biomarkers for Mycobacterium tuberculosis and the potential application in the serodiagnosis of human tuberculosis

A novel multi-component protein vaccine ECP001 containing a protein polypeptide antigen nPstS1 riching in T-cell epitopes showed good immunogenicity and protection in mice

Contact Info

Product

Resources

About